Boditech Med announced the signing of a memorandum of understanding with Novo Integrated Sciences, Inc. that provides for marketing and distribution in North America. Boditech's product line includes technologies that enable accurate, thorough capillary blood tests, based on a small amount of blood from a finger prick. Boditech intends to bring lower-cost, rapid testing that covers many critical areas of medicine, from cardiac health to cancer, to the country.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18,280 KRW | +0.83% | +9.53% | -10.83% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.83% | 293M | |
-26.41% | 16.36B | |
-57.29% | 2.11B | |
+13.19% | 1.79B | |
-15.17% | 1.41B | |
+27.75% | 1.29B | |
+9.28% | 861M | |
-33.05% | 770M | |
-36.55% | 725M | |
+33.73% | 615M |
- Stock Market
- Equities
- A206640 Stock
- News Boditech Med Inc.
- Boditech Med Partners with Novo Integrated Sciences, Inc. to Market and Distribute Lower-Cost, Rapid Testing in North America